Physician profile
Maya Guglin
NPI 1144268871
$29,707.23
in general payments reported to CMS, 2019-2025
26 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $7,785 · 2021: $1,265 · 2022: $2,599 · 2023: $1,050 · 2024: $3,272 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,126 · Travel and Lodging: $2,055 · Consulting Fee: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,125.54 |
| Travel and Lodging | $2,055.15 |
| Consulting Fee | $231.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23,400.41 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Heartmate Touch |
| Cvrx, INC. | $3,035.66 | 2024-2025 | Barostim Neo System |
| Abiomed | $1,327.41 | 2019-2025 | Impella |
| W. L. Gore & Associates, INC. | $600.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $188.98 | 2020-2021 | |
| Novo Nordisk INC | $171.11 | 2023-2024 | Ozempic |
| Edwards Lifesciences Corporation | $120.80 | 2025 | Sapien 3 Ultra Resilia |
| Akcea Therapeutics, INC. | $107.44 | 2019 | |
| Eurofins Viracor, LLC | $99.71 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $93.43 | 2022-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $90.37 | 2023-2025 | Verquvo, Winrevair |
| Atricure, INC. | $83.65 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Pfizer INC. | $65.42 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $56.83 | 2023-2024 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $48.86 | 2024-2025 | Uptravi, Opsynvi, Opsumit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.23 | 2025 | |
| Kestra Medical Technology Services, INC. | $30.00 | 2025 | Assure Wcd |
| Ancora Heart, INC. | $28.15 | 2024 | Accucinch |
| Endotronix, INC. | $27.37 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Astellas Pharma US INC | $20.13 | 2025 | Cresemba |
| Bridgebio Pharma, INC. | $18.44 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $18.04 | 2024 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.65 | 2025 | |
| Boston Scientific Corporation | $14.74 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.40 | 2024 | Livtencity |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Guglin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.